Reuters -- Human Genome Sciences Inc said the U.S. health regulators denied to approve its experimental anthrax drug raxibacumab -- which is being developed for use in the treatment of inhalational anthrax.
Reuters -- Human Genome Sciences Inc said the U.S. health regulators denied to approve its experimental anthrax drug raxibacumab -- which is being developed for use in the treatment of inhalational anthrax.
